Home > Insider Trading > Filing (0001104659-22-108589)

Filing Details

Accession Number:: 0001104659-22-108589
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-10-13 20:52:42
Reporting Period:: 2022-10-11

Accepted Time:: 2022-10-13 20:52:42
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1644963	Avenue Therapeutics Inc.	ATXI	Pharmaceutical Preparations (2834)	474113275

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1759453	Invagen Pharmaceuticals, Inc.	7 Oser Avenue Hauppauge NY 11788		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.0001 Per Share	Disposition	2022-10-11	388,888	$7.71	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, Par Value $0.0001 Per Share	0	Indirect	See Footnote

Footnotes

This Form 4 is being jointly filed on behalf of (i) InvaGen Pharmaceuticals Inc., a New York corporation ("InvaGen"), (ii) Cipla (EU) Limited, a company incorporated in the United Kingdom ("Cipla EU"), and (iii) Cipla Limited, a company incorporated in India ("Cipla Limited") (each of InvaGen, Cipla EU and Cipla Limited, a "Reporting Person", and collectively, the "Reporting Persons"). InvaGen is a wholly-owned direct subsidiary of Cipla EU. Cipla EU is a wholly-owned direct subsidiary of Cipla Limited. Because of the relationship of InvaGen to Cipla EU and Cipla Limited, each such Reporting Person may be deemed to beneficially own the securities covered by this Form 4.
On September 22, 2022, the common stock of Avenue Therapeutics, Inc. (the "Issuer") reverse split 1-for-15, resulting in the 5,833,333 shares of common stock of the Issuer previously reported by the Reporting Persons becoming 388,888 shares of common stock of the Issuer.
On October 11, 2022, pursuant to the terms of the previously announced Stock Repurchase Agreement, dated July 25, 2022, among InvaGen, Fortress Biotech, Inc. and the Issuer, the Issuer repurchased 388,888 shares of common stock of the Issuer from InvaGen for an aggregate purchase price of $3,000,000 (the "Share Repurchase").
As a result of the Share Repurchase and concurrent termination of the Voting and Support Agreement dated November 12, 2018, by and among InvaGen, Madison Pharmaceuticals Inc. and the Issuer, the Reporting Persons no longer have beneficial ownership of the securities previously reported as indirectly owned in the Reporting Persons' Form 3.